Pankreatik Yetmezlik Yönetimi
Özet
Ekzokrin pankreas yetmezliği (EPY), amilaz, tripsin ve lipaz gibi sindirim enzimlerinin eksikliğiyle karakterize, hastaların yaşam kalitesini önemli ölçüde düşüren multifaktöriyel bir hastalıktır. Toplumdaki gerçek insidansı tam olarak bilinmemekle birlikte, yetişkinlerde en sık kronik pankreatit, çocuklarda ise kistik fibrozis nedeniyle gelişmektedir. EPY; gaz, şişkinlik, kilo kaybı ve steatore gibi spesifik olmayan semptomların yanı sıra mineral ve vitamin eksikliklerine bağlı sistemik komplikasyonlara yol açar. Tanısında fekal pankreatit elastaz testi birinci basamak test olarak öne çıkarken, yağ emilim katsayısı altın standart kabul edilir. Hastalığın yönetimi multidisipliner bir yaklaşım gerektirir. Tedavinin temel taşını oluşturan pankreatik enzim replasman tedavisi (PERT), sindirimi normalleştirmeyi ve semptomları kontrol altına almayı amaçlar. PERT dozu; hastalığın şiddetine ve etyolojisine göre ana öğün başına 20-50 bin lipaz ünitesi olarak başlanıp klinik seyre göre ayarlanmalıdır. Yaşam tarzı değişiklikleri kapsamında alkol ve sigaranın bırakılması, sık ve küçük porsiyonlu beslenme önerilir. Standart enzim tedavisine yanıt alınamayan vakalarda, enzim denatürasyonunu önlemek için proton pompa inhibitörleri, safra asitleri ve probiyotikler gibi destek tedavileri sırasıyla sekonder ve üçüncü basamak seçenekler olarak kombinasyona eklenmelidir.
Exocrine pancreatic insufficiency (EPI) is a multifactorial disorder characterized by a deficiency in digestive enzymes such as amylase, trypsin, and lipase, which substantially impairs patients' quality of life. Although its true prevalence remains unknown, it is most frequently caused by chronic pancreatitis in adults and cystic fibrosis in children. EPI manifests through non-specific symptoms including bloating, weight loss, and steatorrhea, and leads to systemic complications from nutrient deficiencies. Diagnosis utilizes fecal pancreatic elastase as a first-line test, while the coefficient of fat absorption remains the gold standard. Effective management demands a multidisciplinary approach. Pancreatic enzyme replacement therapy (PERT) is the cornerstone of treatment, aiming to normalize digestion and alleviate symptoms. PERT should be initiated at 20-50 thousand lipase units per main meal and tailored sequentially based on etiology and clinical response. Lifestyle modifications require absolute cessation of alcohol and smoking, alongside consuming frequent, small, high-calorie meals. For patients showing inadequate response to standard PERT, supportive therapies including proton pump inhibitors, bile acids, and probiotics should be introduced as secondary and tertiary combined treatment options to optimize duodenal pH and nutrient absorption.
Referanslar
Capurso G, Traini M, Piciucchi M, et al. Exocrine pancreatic insufficiency: Prevalence, diagnosis, and management. Clin. Exp. Gastroenterol. 2019, 12, 129–139.
Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr. Opin. Gastroenterol. 2018, 34, 349–354.
Sikkens ECM, Cahen DL, van Eijck C, et al. Patients with exocrine insufficiency due to chronic pancreatitis are undertreated: a Dutch national survey. Pancreatology 2012; 12:71–3.
Duggan SN. Negotiating the complexities of exocrine and endocrine dysfunction in chronic pancreatitis. Proc. Nutr. Soc. 2017, 76, 484–494.
Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early and late onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994, 107, 1481–1487.
Ghodeif AO, Azer SA. Pancreatic Insufficiency. 2021 Jan 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
Löhr JM, Dominguez-Munoz E, Rosendahl J, et al. United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur. Gastroenterol. J. 2017, 5, 153–199.
Perbtani Y, Forsmark CE. Update on the diagnosis and management of exocrine pancreatic insufficiency. F1000Research 2019, 8, 1991.
Armstrong T, Walters E, Varshney S, et al. Deficiencies of micronutrients, altered bowel function, and quality of life during late follow-up after pancreaticoduodenectomy for malignancy. Pancreatology 2002; 2:528–34.
Forsmark C. Diagnosis and management of exocrine pancreatic insufficiency. Curr. Treat. Options Gastroenterol. 2018, 16, 306–315.
Yamabe A, Irisawa A, Shibukawa G, et al. Early diagnosis of chronic pancreatitis: understanding the factors associated with the development of chronic pancreatitis. Fukushima J Med Sci 2017; 63:1–7.
Roberts KJ, Bannister CA, Schrem H. Enzyme replacement improves survival among patients with pancreatic cancer: results of a population based study. Pancreatology 2019; 19:114–21.
Domínguez-Muñoz JE, Nieto-Garcia L, López-Díaz J, et al. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. BMC Cancer 2018; 18:534.
D'Haese JG, Ceyhan GO, Demir IE, et al. Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life. Pancreas 2014; 43:834–41.
Afghani E, Sinha AK, Singh V. An overview of the diagnosis and management of nutrition in chronic pancreatitis. Nutr. Clin. Pract. 2014, 29, 295–311.
Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian association for the study of the pancreas. World J. Gatroenterol. 2013, 19, 7930–7946.
Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol 2011; 26(Suppl 2):12–16.
Diéguez-Castillo C, Jiménez-Luna C, Prados J, et al. State of the Art in Exocrine Pancreatic Insufficiency. Medicina (Kaunas). 2020 Oct 7;56(10):523.
Phillips ME, Hopper AD, Leeds JS, et al. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021 Jun;8(1): e000643.
Pham A, Forsmark C. Chronic pancreatitis: review and update of etiology, risk factors, and management. F1000Res. 2018;7
Nikfarjam M, Wilson JS, Smith RC. Australasian Pancreatic Club Pancreatic Enzyme Replacement Therapy Guidelines Working Group. Diagnosis and management of pancreatic exocrine insufficiency. Med J Aust. 2017 Aug 21;207(4):161-165.
Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013 Nov 14;19(42):7258-66. doi: 10.3748/wjg. v19.i42.7258.
Dutta SK, Hlasko J. Dietary fiber in pancreatic disease: effect of high fiber diet on fat malabsorption in pancreatic insufficiency and in vitro study of the interaction of dietary fiber with pancreatic enzymes. Am J Clin Nutr 1985; 41:517–25.
Sikkens EC, Cahen DL, Koch AD, et al. The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. Pancreatology 2013; 13: 238-242.
Gullo L, Barbara L, Labò G. Effect of cessation of alcohol use on the course of pancreatic dysfunction in alcoholic pancreatitis. Gastroenterology 1988; 95: 1063-1068.
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144: 1252-1261.
Law R, Parsi M, Lopez R, et al. Cigarette smoking is independently associated with chronic pancreatitis. Pancreatology 2010; 10: 54-59.
DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288: 813-815.
Dumasy V, Delhaye M, Cotton F, et al. Fat malabsorption screening in chronic pancreatitis. Am J Gastroenterol 2004; 99: 1350-1354.
Domínguez-Muñoz JE, Iglesias-García J. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is clinical response an appropriate marker for evaluation of therapeutic efficacy? JOP 2010; 11: 158-162.
Domínguez-Muñoz JE. Chronic pancreatitis and persistent steatorrhea: what is the correct dose of enzymes? Clin Gastroenterol Hepatol. 2011 Jul;9(7):541-6.
Toouli J, Biankin AV, Oliver MR, et al. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust 2010; 193: 461-467.
Frulloni L, Falconi M, Gabbrielli A et al. Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis 2010; 42 Suppl 6: S381-S406.
de-Madaria E, Abad-González A, Aparicio JR et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). Pancreatology 2013; 13: 18-28.
Hoffmeister A, Mayerle J, Beglinger C et al. [S3-Consensus guidelines on definition, etiology, diagnosis and medical, endoscopic and surgical management of chronic pancreatitis German Society of Digestive and Metabolic Diseases (DGVS)]. Z Gastroenterol 2012; 50: 1176-1224.
Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastro- enterol 2010; 105: 2276-2286.
Thorat V, Reddy N, Bhatia S, et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo- controlled study. Aliment Pharmacol Ther 2012; 36: 426-436.
Ramesh H, Reddy N, Bhatia S, et al. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric- coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Pancreatology 2013; 13: 133-139.
Pezzilli R. Chronic pancreatitis: Maldigestion, intestinal ecology and intestinal inflammation. World J. Gastroenterol. 2009, 15, 1673–1676.
Akshintala VS, Talukdar R, Singh VK, et al. The Gut microbiome in pancreatic disease. Clin. Gastroenterol. Hepatol. 2019, 17, 290–295.
Hamada S, Masamune A, Nareshima T, et al. Differences in gut microbiota profiles between autoimmune pancreatitis and chronic pancreatitis. Tohoku J. Exp. Med. 2018, 244, 113–117.
